Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JAK2-IN-7 是一种选择性 JAK2抑制剂,对 JAK2,SET-2 和 Ba/F3V617F 细胞的IC50为 3、11.7 和 41 nM。 JAK2-IN-7 的选择性是 JAK1, JAK3,FLT3 的 14 倍以上。JAK2-IN-7 刺激细胞周期停滞在 G0/G1 期,并诱导肿瘤细胞凋亡 (apoptosis),具有抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,680 | 现货 | ||
5 mg | ¥ 3,730 | 现货 | ||
10 mg | ¥ 6,660 | 现货 | ||
25 mg | ¥ 9,880 | 现货 | ||
50 mg | ¥ 13,300 | 现货 | ||
100 mg | ¥ 17,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,780 | 现货 |
产品描述 | JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM for Ba/F3 V617F cells, indicative of its potency and selectivity. This compound demonstrates more than 14-fold selectivity against JAK1, JAK3, and FLT3, underlining its specificity. JAK2-IN-7 effectively induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in tumor cells, manifesting significant antitumor activities [1]. |
体外活性 | JAK2-IN-7 (compound 13ac) (0-1000 nM; 2 hours) inhibits phosphorylation of JAK2 and STAT5 in a dose-dependent manner in SET-2 and Ba/F3-JAK2 V617F cells [1]. JAK2-IN-7 (10-160 nM; 24 hours) induces cell arrest in the G0/G1 phase [1]. JAK2-IN-7 (0.05-1.6 μM; 2 hours) induces apoptosis in SET-2 cells [1]. Cell Cycle Analysis [1] Cell Line: SET-2 cells Concentration: 10-160 nM Incubation Time: 24 hours Result: Induced cell arrest in the G0/G1 phase in a concentration-dependent manner. Apoptosis Analysis [1] Cell Line: SET-2 cells Concentration: 0.05-1.6 μM Incubation Time: 2 hours Result: Induced apoptosis in SET-2 cells. |
体内活性 | JAK2-IN-7 (15-60 mg/kg; p.o.; daily for 16 days) exhibits potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model [1]. JAK2-IN-7 (30-60 mg/kg; p.o.; q.d. for 16 day) significantly ameliorates the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib [1]. Animal Model: SET-2 cell-inoculated xenograft NOD/SCID mouse model [1] Dosage: 15, 30, and 60 mg/kg Administration: Orally daily for 16 days Result: Exhibited a significant tumor growth inhibition of 82.3% without obvious weight change. |
别名 | JAK2-IN-7 |
分子量 | 459.59 |
分子式 | C26H33N7O |
CAS No. | 2593402-36-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (543.96 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1759 mL | 10.8793 mL | 21.7585 mL | 54.3963 mL |
5 mM | 0.4352 mL | 2.1759 mL | 4.3517 mL | 10.8793 mL | |
10 mM | 0.2176 mL | 1.0879 mL | 2.1759 mL | 5.4396 mL | |
20 mM | 0.1088 mL | 0.544 mL | 1.0879 mL | 2.7198 mL | |
50 mM | 0.0435 mL | 0.2176 mL | 0.4352 mL | 1.0879 mL | |
100 mM | 0.0218 mL | 0.1088 mL | 0.2176 mL | 0.544 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JAK2-IN-7 2593402-36-7 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells JAK JAK2IN7 JAK-2-IN-7 JAK2 IN 7 Inhibitor inhibitor inhibit